Imunon (NASDAQ:IMNN – Get Free Report) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Imunon to announce earnings of ($0.61) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 11:00 AM ET.
Imunon (NASDAQ:IMNN – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.33. On average, analysts expect Imunon to post ($2.37) EPS for the current fiscal year and ($2.03) EPS for the next fiscal year.
Imunon Stock Up 0.8%
Shares of NASDAQ IMNN opened at $0.91 on Thursday. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.82 and a current ratio of 1.82. The stock’s 50-day simple moving average is $1.27 and its two-hundred day simple moving average is $2.20. Imunon has a twelve month low of $0.81 and a twelve month high of $4.38.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.00.
Check Out Our Latest Research Report on Imunon
About Imunon
Imunon, Inc (NASDAQ: IMNN) is a clinical-stage biotechnology company focused on developing treatments for cancer and other serious diseases. The company uses proprietary nucleic acid delivery technologies to develop therapeutic candidates designed to stimulate the immune system or deliver genetic instructions directly to target cells.
Imunon’s lead program is GEN-1, an investigational interleukin-12 gene-mediated immunotherapy intended to treat ovarian cancer. The company has evaluated GEN-1 in combination with chemotherapy and other treatments in clinical studies.
Featured Stories
- Five stocks we like better than Imunon
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
